Equity kickers—warrants, options, convertible features, or other equity-linked instruments bundled with debt or investment transactions—serve as return enhancers

Recent pharmaceutical royalty financings have increasingly featured "royalty tail" provisions. In a royalty monetization, an originator (typically a

The final week of January 2026 delivered the largest licensing deal of the year so far, a collapsed mega-merger, and

2025-2026 Market Overview: Record Volume Reshapes the Landscape Before diving into the technical intricacies of liens, it is worth pausing

SLR Investment Corp. (NASDAQ: SLRC) is a New York-based business development company externally managed by SLR Capital Partners, a specialty

Executive Summary Mendra, Inc. is a newly launched San Francisco-based biopharmaceutical company targeting high-unmet-need rare diseases. In January 2026, the

The Gulf Cooperation Council (GCC) pharmaceutical industry is undergoing significant structural changes as sovereign wealth funds deploy capital and local

The Pension Fund Challenge—And Why Royalties Address It Defined benefit pension plans face a structural dilemma: actuarial assumptions of

What Are Indication-Specific Royalties? Indication-specific royalties are royalty financing or licensing arrangements where payments are tied only to sales of

The third week of January, recorded over $10 billion in confirmed and potential transaction value across 30+ biotech, pharmaceutical, and